C4 Therapeutics, Inc. – NASDAQ:CCCC
Founder-led company
C4 Therapeutics stock price today
$2.74
-1.04
-27.7%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
C4 Therapeutics stock price monthly change
-32.92%
month
C4 Therapeutics stock price quarterly change
-32.92%
quarter
C4 Therapeutics stock price yearly change
-26.34%
year
C4 Therapeutics key metrics
Market Cap | 276.00M |
Enterprise value | 216.44M |
P/E | -1.15 |
EV/Sales | 6.96 |
EV/EBITDA | -1.74 |
Price/Sales | 5.11 |
Price/Book | 0.54 |
PEG ratio | 0.02 |
EPS | -2.37 |
Revenue | 20.03M |
EBITDA | -131.08M |
Income | -126.07M |
Revenue Q/Q | -19.15% |
Revenue Y/Y | -26.34% |
Profit margin | -412.19% |
Oper. margin | -416.56% |
Gross margin | 0% |
EBIT margin | -416.56% |
EBITDA margin | -654.25% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeC4 Therapeutics stock price history
C4 Therapeutics stock forecast
C4 Therapeutics financial statements
Average Price Target
$16
Potential upside: 483.94%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 2.66M | -35.92M | -1348.42% |
|---|---|---|---|
| Sep 2023 | 11.07M | -27.03M | -244.19% |
| Dec 2023 | 3.26M | -34.75M | -1065.75% |
| Mar 2024 | 3.03M | -28.36M | -933.23% |
| 2024-02-22 | -0.67 | -0.68 |
|---|
| Jun 2023 | 375008000 | 141.30M | 37.68% |
|---|---|---|---|
| Sep 2023 | 333013000 | 116.98M | 35.13% |
| Dec 2023 | 376451000 | 130.33M | 34.62% |
| Mar 2024 | 398371000 | 140.08M | 35.17% |
| Jun 2023 | -18.99M | 15.14M | -746K |
|---|---|---|---|
| Sep 2023 | -30.70M | 57.72M | -10.75M |
| Dec 2023 | -24.00M | 31.94M | 57.67M |
| Mar 2024 | -18.11M | -53.39M | 34.58M |
C4 Therapeutics alternative data
| Aug 2023 | 146 |
|---|---|
| Sep 2023 | 146 |
| Oct 2023 | 146 |
| Nov 2023 | 146 |
| Dec 2023 | 146 |
| Jan 2024 | 146 |
| Feb 2024 | 146 |
| Mar 2024 | 145 |
| Apr 2024 | 145 |
| May 2024 | 145 |
| Jun 2024 | 145 |
| Jul 2024 | 145 |
C4 Therapeutics other data
27.54%
-52.43%
of CCCC is owned by hedge funds
62
-51
13.45M
-25.66M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Apr 2022 | 10000 | 0 |
| Feb 2023 | 5667 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | BOYLE SCOTT N officer: Chief Business Officer | Common Stock | 3,750 | N/A | N/A | ||
Option | BOYLE SCOTT N officer: Chief Business Officer | Performance Restricted Stock Units | 3,750 | N/A | N/A | ||
Option | ADAMS KENDRA officer: Chief Financial Officer | Common Stock | 3,750 | N/A | N/A | ||
Option | ADAMS KENDRA officer: Chief Financial Officer | Performance Restricted Stock Units | 3,750 | N/A | N/A | ||
Option | SCHICK KELLY officer: Chief People Officer | Common Stock | 3,750 | N/A | N/A | ||
Option | SCHICK KELLY officer: Chief People Officer | Performance Restricted Stock Units | 3,750 | N/A | N/A | ||
Option | SIEGEL JOLIE officer: Chief Legal Officer | Common Stock | 3,750 | N/A | N/A | ||
Option | SIEGEL JOLIE officer: Chief Legal Officer | Performance Restricted Stock Units | 3,750 | N/A | N/A | ||
Option | HIRSCH ANDREW director, officer.. | Common Stock | 12,500 | N/A | N/A | ||
Option | HIRSCH ANDREW director, officer.. | Performance Restricted Stock Units | 12,500 | N/A | N/A |
| Patent |
|---|
Application Filling date: 14 May 2020 Issue date: 11 Aug 2022 |
Grant Filling date: 4 Mar 2020 Issue date: 2 Aug 2022 |
Application Filling date: 2 Dec 2021 Issue date: 31 Mar 2022 |
Grant Filling date: 4 Mar 2020 Issue date: 22 Feb 2022 |
Grant Filling date: 22 May 2020 Issue date: 30 Nov 2021 |
Application Filling date: 4 Mar 2021 Issue date: 1 Jul 2021 |
Application Filling date: 22 May 2020 Issue date: 15 Apr 2021 |
Application Filling date: 24 Nov 2020 Issue date: 11 Mar 2021 |
Application Filling date: 16 Oct 2020 Issue date: 4 Feb 2021 |
Grant Filling date: 11 May 2020 Issue date: 2 Feb 2021 |
-
What's the price of C4 Therapeutics stock today?
One share of C4 Therapeutics stock can currently be purchased for approximately $2.74.
-
When is C4 Therapeutics's next earnings date?
Unfortunately, C4 Therapeutics's (CCCC) next earnings date is currently unknown.
-
Does C4 Therapeutics pay dividends?
No, C4 Therapeutics does not pay dividends.
-
How much money does C4 Therapeutics make?
C4 Therapeutics has a market capitalization of 276.00M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 33.25% to 20.76M US dollars. C4 Therapeutics made a loss 132.49M US dollars in net income (profit) last year or -$0.68 on an earnings per share basis.
-
What is C4 Therapeutics's stock symbol?
C4 Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "CCCC".
-
What is C4 Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of C4 Therapeutics?
Shares of C4 Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are C4 Therapeutics's key executives?
C4 Therapeutics's management team includes the following people:
- Dr. Adam S. Crystal M.D., Ph.D. Chief Medical Officer(age: 48, pay: $661,550)
- Mr. Andrew J. Hirsch Chief Executive Officer, Pres & Director(age: 54, pay: $607,960)
- Mr. Marc A. Cohen Co-Founder, Executive Chairman & Sec.(age: 62, pay: $69,500)
- Dr. Kenneth C. Anderson M.D., Ph.D. Co-Founder, Independent Director & Member of Scientific Advisory Board(age: 74, pay: $27,500)
-
Is C4 Therapeutics founder-led company?
Yes, C4 Therapeutics is a company led by its founders Mr. Marc A. Cohen and Dr. Kenneth C. Anderson M.D., Ph.D..
-
How many employees does C4 Therapeutics have?
As Jul 2024, C4 Therapeutics employs 145 workers.
-
When C4 Therapeutics went public?
C4 Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 2 Oct 2020.
-
What is C4 Therapeutics's official website?
The official website for C4 Therapeutics is c4therapeutics.com.
-
Where are C4 Therapeutics's headquarters?
C4 Therapeutics is headquartered at 490 Arsenal Way, Watertown, MA.
-
How can i contact C4 Therapeutics?
C4 Therapeutics's mailing address is 490 Arsenal Way, Watertown, MA and company can be reached via phone at +61 72310700.
-
What is C4 Therapeutics stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for C4 Therapeutics in the last 12 months, the avarage price target is $16. The average price target represents a 483.94% change from the last price of $2.74.
C4 Therapeutics company profile:
C4 Therapeutics, Inc.
c4therapeutics.comExchange:
NASDAQ
Full time employees:
145
Industry:
Biotechnology
Sector:
Healthcare
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
490 Arsenal Way
Watertown, MA 02472
Watertown, MA 02472
CIK: 0001662579
ISIN: US12529R1077
CUSIP: 12529R107
